Related Experiment Video
Updated: Apr 28, 2026
A High-Throughput Comet Assay Approach for Assessing Cellular DNA Damage
Published on: May 10, 2022
Nested PCR for mtDNA-4977-bp deletion and comet assay for DNA damage - a combined method for radiosensitivity
Jianguo Li1, Yan Wang2, Liqing DU2
1Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin 300192, P.R. China ; Department of Human Anatomy, The Medical School of Inner Mongolia University for the Nationalities, Tongliao, Neimenggu 028041, P.R. China.
Abstract:
To identify an effective method of evaluating the radiosensitivity of human tumor cell lines in vitro, the present study adopted mtDNA-4977-bp deletion coupled with comet assay. The three human tumor cell lines applied were HepG2, EC-9706 and MCF-7. The surviving fraction (SF), ratio of the mtDNA-4977-bp deletion and DNA damage were detected by MTT assay, nested polymerase chain reaction (PCR) technique and comet assay, respectively. Clearly, lower SFs were found for the HepG2 and EC-9706 cells as compared with the MCF-7 cells following irradiation at doses of 2, 4 and 8 Gy, indicating a higher radiosensitivity for the HepG2 and EC-9706 cells. Additionally, no significant differences were identified in the mtDNA-4977-bp deletions found among HepG2, EC-9706 and MCF-7 cells by PCR following 1- or 4-Gy γ-ray irradiation, while increased deletion ratios of mtDNA-4977 bp were observed in HepG2 and EC-9706 cells following 8-Gy irradiation, in contrast to decreases in MCF-7 cells. The most notable differences among these three tumor cell lines were observed by comet assay following 8-Gy γ-ray irradiation. A combined method of nested PCR and comet assay, therefore, is the most effective and accurate method in evaluating the radiosensitivity of tumor cells.
Insights
This study evaluated tumor cell radiosensitivity using mitochondrial DNA deletion and comet assays. A combined nested PCR and comet assay approach proved most effective for accurate radiosensitivity assessment in human tumor cell lines.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy Research
Background:
- Assessing cancer cell radiosensitivity is crucial for effective radiotherapy planning.
- Existing methods may not fully capture the complex cellular responses to radiation.
- Mitochondrial DNA (mtDNA) integrity and DNA damage are potential biomarkers for radiosensitivity.
Purpose of the Study:
- To identify an effective *in vitro* method for evaluating human tumor cell line radiosensitivity.
- To compare the efficacy of MTT assay, mtDNA-4977-bp deletion detection, and comet assay.
- To determine the optimal combined approach for radiosensitivity assessment.
Main Methods:
- Utilized three human tumor cell lines: HepG2, EC-9706, and MCF-7.
- Employed MTT assay for surviving fraction (SF), nested PCR for mtDNA-4977-bp deletion ratios, and comet assay for DNA damage.
- Exposed cells to varying doses of gamma-ray irradiation (2, 4, and 8 Gy).
Main Results:
- HepG2 and EC-9706 cells exhibited higher radiosensitivity (lower SF) compared to MCF-7 cells.
- Increased mtDNA-4977-bp deletion ratios were observed in HepG2 and EC-9706 cells at 8 Gy, unlike MCF-7 cells.
- Comet assay revealed the most significant differences in DNA damage among cell lines at 8 Gy.
Conclusions:
- A combined approach using nested PCR for mtDNA-4977-bp deletion and comet assay for DNA damage is the most effective and accurate method for evaluating tumor cell radiosensitivity *in vitro*.
- This integrated method provides a more comprehensive understanding of cellular response to radiation.
- Findings support the utility of these molecular markers in predicting treatment outcomes.
More Related Videos
04:36Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
10:59CometChip: A High-throughput 96-Well Platform for Measuring DNA Damage in Microarrayed Human Cells
Published on: October 18, 2014